Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects

NCT03681158 | Completed Phase 1

• 3 other identifiers: BEX153162017-004987-36U1111-1205-1651
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

Primary Objectives:

• To determine the excretion balance and systemic exposure of radioactivity after oral administration of \[14C\]-sodium valproate (VPA) .
• To determine the pharmacokinetics of sodium VPA and metabolite(s) and its contribution to the overall exposure of radioactivity.
• To collect samples in order to determine the metabolic pathways of sodium VPA and identify the chemical structures and main excretion route of the main metabolites. Secondary Objective: To assess the clinical and biological tolerability of oral solution of sodium VPA.

Conditions

Epilepsy

Outcome Measures

Primary Outcomes (10)

• Percentage of radioactive dose excreted in urine and feces

  Fractional and cumulative percentage of radioactive dose excreted in urine and feces

  Day 1 to Day 43

• Assessment of key metabolite(s) of sodium valproate

  key metabolite(s) of sodium valproate will be assessed in plasma, urine and feces.

  Day 1 to Day 43

• Assessment of PK parameters: Cmax

  Maximum plasma or blood concentration observed

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: tmax

  Time to reach Cmax (tmax)

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: AUClast

  Area under the plasma concentration versus time curve calculated from time zero to the real time, tlast (time corresponding to the last concentration above the limit of quantification, Clast (AUClast)

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: AUC

  Area under the plasma concentration versus time curve extrapolated to infinity (AUC)

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: t1/2z

  Terminal half-life associated with the terminal slope (λz) (t1/2z) in plasma, blood radioactivity and plasma VPA

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: B/P (blood/plasma radioactivity ratio)

  Blood to plasma radioactivity ratio calculated at each time point

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: RCmax (VPA to radioactivity ratio for plasma Cmax)

  RCmax is calculated as Cmax(VPA)/Cmax (radioactivity)

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

• Assessment of PK parameters: RAUC (VPA to radioactivity ratio for plasma AUC)

  RAUC is calculated as AUC(VPA)/AUC (radioactivity)

  Day 1 to 8, Day 12 to Day 15, Day 22, Day 29, Day 36, Day 43

Secondary Outcomes (1)

• Safety- Adverse Events

  From day -1 to 43

Study Arms (1)

sodium valproate

EXPERIMENTAL

Single oral dose of sodium valproate containing \[14C\]-sodium VPA

Drug: sodium valproate

Interventions

sodium valproate DRUG

Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral

Also known as: LA40220

sodium valproate

Eligibility Criteria

• Age: 30 Years - 60 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Female subjects, between 30 and 60 years of age, inclusive.
• Body weight between 40.0 and 90.0 kg, inclusive, body mass index between 18.0 and 30.0 kg/m2, inclusive.
• Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
• Normal vital signs after 10 minutes resting in supine position: 95 mmHg \< systolic blood pressure (SBP) \<140 mmHg or, for subjects over 45 years of age, \<150 mmHg, 45 mmHg \< diastolic blood pressure (DBP) \<90 mmHg, 40 bpm \< heart rate (HR) \<100 bpm
• Standard 12-lead electrocardiogram (ECG) parameters after 10 minutes resting in supine position in the following ranges; 120 ms\<PR\<220 ms, QRS\<120 ms, QTc≤450 ms and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not clinically relevant, or for subjects over 45 years of age, standard 12-lead ECG without clinically significant abnormality, in the judgment of the Investigator, with QTc≤470 ms.
• Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects; however, serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase), and total bilirubin (unless the subject has documented Gilbert syndrome) should not exceed the upper laboratory norm.
• Surgically and permanently sterile (hysterectomy, bilateral salpingectomy or bilateral salpingo-oophorectomy) at least 3 months earlier or postmenopausal. Menopause is defined as being amenorrheic for at least 2 years with plasma FSH level \> 30 UI/L. No additional contraception is required.
• Having given written informed consent prior to undertaking any study-related procedure.
• Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
• Not under any administrative or legal supervision.
• Normal renal function as expressed by a creatinine clearance \> 80 mL/min as calculated by the Cockroft and Gault formula

You may not qualify if:

• Any subject with specific dietary habits, such as vegan.
• Any subject with irregular bowel habits (more than 3 bowel movements/day or less than 1 every 2 days).
• Any subject undergoing dental care or presenting with dental caries.
• Any subject who is occupationally exposed to radiation as defined in the Ionising Radiations Regulations 2017.
• Participation in a trial with 14C-radiolabelled medication in the 12 months preceding the study.
• Radiation exposure, including that from the present study and radiopharmaceuticals or radionuclides in therapeutic or diagnostic procedures, but excluding background radiation, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years.
• Poor metabolizer status for CYP2C9, CYP2C19, CYP2D6 (by genotyping).
• Any contra-indications to sodium VPA according to the applicable labeling (including personal or family history of severe hepatic dysfunction, urea cycle disorders, porphyria, hypersensitivity to valproate, active liver disease, pregnancy, child bearing potential) and patients known to have mitochondrial disorders caused by mutations in the nuclear gene encoding mitochondrial enzyme polymerase γ (POLG, e.g. Alpers-Huttenlocher Syndrome).
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sponsors & Collaborators

• Sanofi: lead

Study Sites (1)

Investigational site number

Nottingham, United Kingdom

Location

MeSH Terms

Conditions

Epilepsy

Interventions

Valproic Acid

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Pentanoic Acids; Valerates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Fatty Acids, Volatile; Fatty Acids; Lipids

Study Officials

• Clinical Sciences & Operations

  Sanofi

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 14, 2018
• First Posted: September 21, 2018
• Study Start: October 5, 2018
• Primary Completion: April 11, 2019
• Study Completion: April 11, 2019
• Last Updated: April 25, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will share

Locations

GB (1)